



Universiteit  
Leiden  
The Netherlands

## Measurement of cortical, nerve, and muscle excitability in early phase clinical drug development

Ruijs, T.Q.

### Citation

Ruijs, T. Q. (2024, April 18). *Measurement of cortical, nerve, and muscle excitability in early phase clinical drug development*. Retrieved from <https://hdl.handle.net/1887/3736584>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3736584>

**Note:** To cite this publication please use the final published version (if applicable).

## CURRICULUM VITAE

Titia Quirine Ruijs, born in 's-Gravenhage, 1990, graduated from secondary school in 2008 (Gymnasium, *Willem de Zwijger College*, Bussum). She studied abroad for one year as an international student (*St. Clare's International College*, Oxford and *Lorenzo de' Medici Institute*, Florence), after which she studied Architecture at *Delft University of Technology* in 2009-2010. In 2010 she started studying Medicine at the *Erasmus University Rotterdam*. As part of her master's degree, Titia did a research elective at the *University of Edinburgh*, where she investigated the use of *Optical Coherence Tomography* in chronic kidney disease. In 2017 she received her medical degree. The same year, she started as PhD candidate and project leader of early phase drug studies at the *Centre for Human Drug Research*, Leiden. As PhD candidate at *Leiden University*, Titia investigated pharmacodynamic biomarkers for cortical, nerve, and muscle excitability in early phase clinical drug development, under supervision of Prof. Dr. G.J. Groeneveld. Titia lives in Amsterdam with her husband Laurence Moss, and their son Maurits.

## LIST OF PUBLICATIONS

**Ruijs TQ**, Koopmans IW, de Kam ML, Tannemaat MR, Groeneveld GJ, Heuberger JAAC. Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double-blind placebo-controlled cross-over study. *Clin Transl Sci.* 2022;15(12):2971-2981. doi:<https://doi.org/10.1111/cts.13418>

**Ruijs TQ**, Koopmans IW, de Kam ML, et al. Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. *Clin Pharmacol Ther.* 2022;112(5):1008-1019. doi:<https://doi.org/10.1002/cpt.2694>

**Ruijs TQ**, Heuberger JAAC, de Goede AA, et al. Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double-blind, placebo-controlled, cross-over study. *Br J Clin Pharmacol.* 2022;88(6):2926-2937. doi:<https://doi.org/10.1111/bcp.15232>

O'Donnell P, Dijkstra FM, Damar U, Quanhong L, de Goede AA, Xu L, Pascual-Leone A, Buhl DL, Zuiker R, **Ruijs TQ**, Heuberger JAAC, MacMullin P, Lubell M, Asgharnejad M, Murthy V, Rotenberg A, Jacobs GE, Rosen L. Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation. *Transl Psychiatry.* 2021 May 27;11(1):325. doi: [10.1038/s41398-021-01451-2](https://doi.org/10.1038/s41398-021-01451-2).

Balmforth C, van Bragt JJ, **Ruijs T**, Cameron JR, Kimmitt R, Moorhouse R, Czopek A, Hu MK, Gallacher PJ, Dear JW, Borooah S. Choriorretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. *JCI insight.* 2016 Dec 8;1(20).